NASDAQ:HRTX Heron Therapeutics Q1 2026 Earnings Report $1.23 +0.01 (+0.82%) Closing price 04:00 PM EasternExtended Trading$1.20 -0.03 (-2.44%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Heron Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.03Beat/MissN/AOne Year Ago EPSN/AHeron Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$36.72 millionBeat/MissN/AYoY Revenue GrowthN/AHeron Therapeutics Announcement DetailsQuarterQ1 2026Date5/11/2026TimeBefore Market OpensConference Call DateMonday, May 11, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Heron Therapeutics Earnings HeadlinesHeron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026April 27, 2026 | globenewswire.comHeron (HRTX) Q4 2025 Earnings Call TranscriptFebruary 28, 2026 | fool.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 5 at 1:00 AM | Profits Run (Ad)Heron Therapeutics, Inc. Q4 2025 Earnings Call SummaryFebruary 27, 2026 | finance.yahoo.comHeron Therapeutics Inc (HRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...February 26, 2026 | finance.yahoo.comHeron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial ResultsFebruary 26, 2026 | globenewswire.comSee More Heron Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Heron Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Heron Therapeutics and other key companies, straight to your email. Email Address About Heron TherapeuticsHeron Therapeutics (NASDAQ:HRTX) is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids. Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S. Food and Drug Administration approval in 2016 for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. The company also advanced HTX-019, an injectable emulsion formulation of aprepitant, which obtained FDA approval as the first non-polyethylene glycol formulation for acute CINV prophylaxis in adults. The company’s most advanced pipeline candidate is HTX-011, an investigational, long-acting, non-opioid local anesthetic that combines bupivacaine and low-dose meloxicam. HTX-011 is designed to provide extended post-operative analgesia and has been evaluated in Phase III trials across multiple surgical settings. In addition to HTX-011, Heron is developing other drug candidates to address various analgesic and supportive care needs and is exploring strategic collaborations to broaden the commercial reach of its portfolio. Founded in 2011 and headquartered in Redwood City, California, Heron Therapeutics completed its initial public offering in 2015 and is listed on Nasdaq under the ticker HRTX. The company primarily serves the U.S. market and is pursuing global partnerships to expand its geographic footprint. Heron’s leadership team comprises industry veterans with expertise in clinical development, regulatory affairs and commercialization, supporting the company’s mission to deliver innovative treatments that enhance patient care.View Heron Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings ARM (5/6/2026)AppLovin (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
